Lumida
/AGIO
⌘K
Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

AGIO
$39.61USD+2.30%+0.89 today

MARKET CAP

2.4B

P/E (TTM)

FWD P/E

DAY RANGE

$38 – $40

52W RANGE

$22
$46

AI Summary

Stalk
Sell NowMedium

AGIO has transitioned into Stage 3 distribution, with an active Blow-Off Top marking the terminal phase and short-term EMAs now acting as resistance. Price is rejecting at the 9EMA/21EMA zone after a shallow pullback, confirming a medium-term bearish bias. Short-term conditions also favor continued downside as overbought pressures unwind and rallies fail. Therefore, execution focuses on Sell Now on rallies into the 9EMA/21EMA area to participate in the downtrend.

  • Q1 2026 revenue surged 138% YoY to $20.7M, driven by Acvesme U.S. launch
  • Phase III RISE UP trial showed significant sickle cell disease benefits for mitapivat
  • Stock trades at 35.9× price-to-sales, high relative to peers
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRIC
TREND